Healthcare >> Analyst Interviews >> March 24, 2003
ROBERT HAZLETT is a Director and senior research analyst, with a
focus on large capitalization and specialty pharmaceutical
companies, at Robinson Humphrey. He has seven years' experience
covering large capitalization and specialty pharmaceuticals for
Lehman Brothers, UBS Securities, and Robertson Stephens. His
research has been recognized by the Reuters and Institutional
Investor polls. Prior to pharmaceutical research, he spent seven
years as a trader and portfolio manager in the taxable fixed
income markets with the Bank of New York and U.S. Trust. He is a
graduate of Yale University, with a degree in economics, and of
Columbia University School of Business, with an MBA and a
concentration in finance. Profile
Mr. Hazlett: I cover many companies in the large capitalization
pharmaceutical sector, including Bristol-Myers (BMY), Eli
